Warning Letter — Peak Performance Peptides
The FDA issued a warning letter to Peak Performance Peptides on August 24, 2026, following an evaluation by the Center for Drug Evaluation and Research (CDER). The source indicates enforcement action related to regulatory compliance concerns for the company's products.
This action affects Peak Performance Peptides and companies involved in the distribution and marketing of peptide-based products, as well as regulatory and quality departments overseeing therapeutic claims.
This letter indicates continued CDER oversight of the peptide industry, specifically regarding the marketing of substances that may be classified as unapproved new drugs. Regulatory teams should interpret this as a signal that the FDA remains focused on firms bypassing the formal drug approval process while making therapeutic representations.
Review all digital and physical marketing materials for unapproved therapeutic claims. Ensure that products marketed as supplements or peptides do not include language suggesting the treatment of specific diseases or physiological conditions without valid drug approvals.
FDA Warning Letter issued to: Peak Performance Peptides. 08/24/2026 — Center for Drug Evaluation and Research (CDER). Source: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/peak-performance-peptides-735127-08242026
Open in openFDA / FDA.gov